One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
A social dimension for brain health: the mounting pressure
doi : 10.1016/S1474-4422(21)00295-7
Volume 20, Issue 10, October 2021, Page 773
Integrated approach to stroke burden: are we doing enough?
Jeyaraj DuraiPandianabcIvy AnneSebastiand
doi : 10.1016/S1474-4422(21)00287-8
Volume 20, Issue 10, October 2021, Pages 774-775
Levosimendan for amyotrophic lateral sclerosis
Mamede deCarvalhoabMichaelSwashac
doi : 10.1016/S1474-4422(21)00255-6
Volume 20, Issue 10, October 2021, Pages 775-777
Buying time for infants with spinal muscular atrophy
Ludovan der Pola
doi : 10.1016/S1474-4422(21)00291-X
Volume 20, Issue 10, October 2021, Pages 777-779
Lessons to be learned in intracerebral haemorrhage research
ValeriaCasoaMaria GiuliaMosconia
doi : 10.1016/S1474-4422(21)00296-9
Volume 20, Issue 10, October 2021, Pages 779-780
Autonomic failure: a neglected presentation of Parkinson's disease
AlessandraFanciulliaGregor KWenningab
doi : 10.1016/S1474-4422(21)00292-1
Volume 20, Issue 10, October 2021, Pages 781-782
Pimavanserin and dementia-related psychosis: can HARMONY prevail?
Kathy YLiuaRobertHowarda
doi : 10.1016/S1474-4422(21)00257-X
Volume 20, Issue 10, October 2021, Pages 783-784
Thank you to our peer reviewers in 2020
LauraHart
doi : 10.1016/S1474-4422(21)00294-5
Volume 20, Issue 10, October 2021, Page 785
Neuropathology of progressive supranuclear palsy after treatment with tilavonemab
ShunsukeKogaaDennis WDicksonaZbigniew KWszolekb
doi : 10.1016/S1474-4422(21)00283-0
Volume 20, Issue 10, October 2021, Pages 786-787
Neuropathology of progressive supranuclear palsy after treatment with tilavonemab – Author's reply
Günter UHöglingerabc
doi : 10.1016/S1474-4422(21)00284-2
Volume 20, Issue 10, October 2021, Pages 787-788
Crowdfunding for neuromuscular disease treatment: the ethical implications
AngusLivingstoneaLaurentServaisbdDominic J CWilkinsoncef
doi : 10.1016/S1474-4422(21)00266-0
Volume 20, Issue 10, October 2021, Pages 788-789
Correction to Lancet Neurol 2021; 20: 739–52
doi : 10.1016/S1474-4422(21)00286-6
Volume 20, Issue 10, October 2021, Page e6
Correction to Lancet Neurol 2021; 20: 762–72
doi : 10.1016/S1474-4422(21)00290-8
Volume 20, Issue 10, October 2021, Page e6
Correction to Lancet Neurol 2021; 20: 687–89
doi : 10.1016/S1474-4422(21)00288-X
Volume 20, Issue 10, October 2021, Page e6
Correction to Lancet Neurol 2021; 20: 703–04
doi : 10.1016/S1474-4422(21)00282-9
Volume 20, Issue 10, October 2021, Page e6
Michael Moskowitz: solving the puzzle of migraine
UdaniSamarasekera
doi : 10.1016/S1474-4422(21)00141-1
Volume 20, Issue 10, October 2021, Page 790
Pseudomedicine for sports concussions in the USA
Kathleen EBachynskiJames MSmoliga
doi : 10.1016/S1474-4422(19)30250-9
Volume 20, Issue 10, October 2021, Pages 791-792
Anatomy embroiders function in Purkinje cells
DavidAttwellArpan RMehta
doi : 10.1016/S1474-4422(21)00281-7
Volume 20, Issue 10, October 2021, Page 793
Pratiti (Mimi) Bandopadhayay
doi : 10.1016/S1474-4422(21)00293-3
Volume 20, Issue 10, October 2021, Page 793
The social network of functional neurological disorderSuzanne O'Sullivan, The Sleeping Beauties and Other Stories of Mystery Illness, Picador (2021), p. 336, £16·99, ISBN: 9781529010558
JonStone
doi : 10.1016/S1474-4422(21)00207-6
Volume 20, Issue 10, October 2021, Page 794
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
doi : 10.1016/S1474-4422(21)00252-0
Volume 20, Issue 10, October 2021, Pages 795-820
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial
ProfMeritCudkowiczMDaAngelaGengeMDbProfNicholasMaragakisMDcProfSusannePetriMDdProfLeonardvan den BergMDeValtteri VAhoMDfToniSarapohjaMScfMikkoKuoppamäkiMDfChrisGarrattMBChBfProfAmmarAl-ChalabiFRCPg
doi : 10.1016/S1474-4422(21)00242-8
Volume 20, Issue 10, October 2021, Pages 821-831
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
ProfEugenioMercuriMDabProfFrancescoMuntoniMDcdeGiovanniBaranelloMDcfRiccardoMassonMDfProfOdileBoespflug-TanguyMDghClaudioBrunoMDiStefaniaCortiMDjkAuroreDaronMDlProfNicolasDeconinckMDnoProfLaurentServaisMDgmpProfVolkerStraubMDqHaojunOuyangPhDrDeepaChandMDrsSitraTauscher-WisniewskiMDrNunoMendoncaMDtArseniyLavrovMDu
doi : 10.1016/S1474-4422(21)00251-9
Volume 20, Issue 10, October 2021, Pages 832-841
Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial
doi : 10.1016/S1474-4422(21)00264-7
Volume 20, Issue 10, October 2021, Pages 842-853
Heart health meets cognitive health: evidence on the role of blood pressure
PriyaPaltaPhDabProfMarilyn SAlbertPhDcProfRebecca FGottesmanMDd
doi : 10.1016/S1474-4422(21)00248-9
Volume 20, Issue 10, October 2021, Pages 854-867
Parkinson's disease outside the brain: targeting the autonomic nervous system
ProfYehonatanSharabiMDacGad DVatinePhDdAvrahamAshkenaziPhDab
doi : 10.1016/S1474-4422(21)00219-2
Volume 20, Issue 10, October 2021, Pages 868-876
